|
SNP genotypes
|
Total (n)
|
Adverse events
| |
OR (95% CI)
|
|---|
|
Yes (n, %)
|
No (n)
|
|---|
|
rs3743527
| |
Myelosuppression
| | | |
|
CC
|
63
|
48 (76.2)
|
15
| |
1.00 (reference)
|
|
TC
|
108
|
85 (78.7)
|
23
|
0.703
|
1.155 (0.51–2.422)
|
|
TT
|
35
|
34 (97.1)
|
1
|
0.007
|
10.625 (1.339–84.317)
|
|
TC+TTa
|
143
|
119 (83.2)
|
24
|
0.236
|
1.549 (0.749–3.206)
|
|
rs212091
| |
Myelosuppression
| | | |
|
AA
|
122
|
107 (87.7)
|
15
| |
1.00 (reference)
|
|
AG
|
72
|
51 (70.8)
|
21
|
0.003
|
0.340 (0.162–0.715)
|
|
GG
|
12
|
9 (75.0)
|
3
|
0.431
|
0.421 (0.102–1.729)
|
|
AG+GGa
|
84
|
60 (71.4)
|
24
|
0.003
|
0.350 (0.171–0.719)
|
|
rs212090
| |
Gastrointestinal reaction
| | | |
|
TT
|
135
|
37 (27.4)
|
98
| |
1.00 (reference)
|
|
AT
|
63
|
29 (46.0)
|
34
|
0.010
|
2.259 (1.211–4.213)
|
|
AA
|
8
|
0 (0)
|
8
|
0.192
|
–
|
|
AA+ATa
|
71
|
29 (40.8)
|
42
|
0.049
|
1.829 (0.998–3.35)
|
|
rs9024
| |
Cardiotoxicity
| | | |
|
GG
|
123
|
2 (1.6)
|
121
| |
1.00 (reference)
|
|
GA
|
69
|
7 (10.1)
|
62
|
0.020
|
6.831 (1.378–33.866)
|
|
AA
|
14
|
2 (14.3)
|
12
|
0.052
|
10.083 (1.301–78.151)
|
|
GA+AAa
|
83
|
9 (10.8)
|
74
|
0.010
|
7.358 (1.547–34.989)
|
- Italic values indicate statistical significance
-
aThe dominant model
